CNBX Pharmaceuticals Inc. (CNBX)
USD 0.01
(31.58%)
USD 0.01
(31.58%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.71 Million USD | 1.56% |
| 2022 | -3.76 Million USD | -51.37% |
| 2021 | -2.48 Million USD | 20.0% |
| 2020 | -3.11 Million USD | -374.73% |
| 2019 | 1.13 Million USD | 130.0% |
| 2018 | -3.77 Million USD | -95.29% |
| 2017 | -1.93 Million USD | -529.54% |
| 2016 | -307.18 Thousand USD | 43.26% |
| 2015 | -541.38 Thousand USD | -100.51% |
| 2014 | -270 Thousand USD | -378.72% |
| 2013 | -56.4 Thousand USD | -3314.1% |
| 2012 | -1652.00 USD | 98.46% |
| 2011 | -107.31 Thousand USD | 6.67% |
| 2010 | -114.98 Thousand USD | -0.05% |
| 2009 | -114.92 Thousand USD | -318.53% |
| 2008 | -27.45 Thousand USD | -18.34% |
| 2007 | -23.2 Thousand USD | -15.89% |
| 2006 | -20.02 Thousand USD | -1012.28% |
| 2005 | -1800.00 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -325.45 Thousand USD | -82.31% |
| 2024 Q1 | -178.52 Thousand USD | 68.87% |
| 2024 Q3 | -130.63 Thousand USD | 59.86% |
| 2023 Q1 | -368.54 Thousand USD | 23.39% |
| 2023 Q4 | -573.55 Thousand USD | -231.38% |
| 2023 FY | -3.71 Million USD | 1.56% |
| 2023 Q2 | -2.62 Million USD | -612.07% |
| 2023 Q3 | -173.08 Thousand USD | 93.4% |
| 2022 Q3 | -728.29 Thousand USD | 58.32% |
| 2022 FY | -3.76 Million USD | -51.37% |
| 2022 Q1 | -1.32 Million USD | -94.23% |
| 2022 Q2 | -1.74 Million USD | -32.08% |
| 2022 Q4 | -481.06 Thousand USD | 33.95% |
| 2021 Q4 | -681.15 Thousand USD | 48.54% |
| 2021 FY | -2.48 Million USD | 20.0% |
| 2021 Q1 | -654.76 Thousand USD | 10.52% |
| 2021 Q2 | -534.75 Thousand USD | 18.33% |
| 2021 Q3 | -1.32 Million USD | -147.55% |
| 2020 FY | -3.11 Million USD | -374.73% |
| 2020 Q3 | -725.67 Thousand USD | 16.38% |
| 2020 Q2 | -867.86 Thousand USD | 83.12% |
| 2020 Q1 | -5.14 Million USD | -269.07% |
| 2020 Q4 | -731.72 Thousand USD | -0.83% |
| 2019 FY | 1.13 Million USD | 130.0% |
| 2019 Q3 | -547.44 Thousand USD | -114.68% |
| 2019 Q1 | -655.97 Thousand USD | 10.42% |
| 2019 Q2 | 3.72 Million USD | 668.57% |
| 2019 Q4 | -1.39 Million USD | -154.5% |
| 2018 Q1 | -537.5 Thousand USD | 51.27% |
| 2018 Q4 | -732.27 Thousand USD | 16.0% |
| 2018 FY | -3.77 Million USD | -95.29% |
| 2018 Q3 | -871.77 Thousand USD | 46.68% |
| 2018 Q2 | -1.63 Million USD | -204.2% |
| 2017 Q1 | -147.01 Thousand USD | -114.55% |
| 2017 Q4 | -1.1 Million USD | -349.46% |
| 2017 Q3 | -245.42 Thousand USD | 44.0% |
| 2017 FY | -1.93 Million USD | -529.54% |
| 2017 Q2 | -438.29 Thousand USD | -198.13% |
| 2016 FY | -307.18 Thousand USD | 43.26% |
| 2016 Q3 | -26.48 Thousand USD | 81.98% |
| 2016 Q1 | 440.91 Thousand USD | 315.17% |
| 2016 Q2 | -146.92 Thousand USD | -133.32% |
| 2016 Q4 | -68.52 Thousand USD | -158.77% |
| 2015 Q2 | -56.85 Thousand USD | 55.47% |
| 2015 FY | -541.38 Thousand USD | -100.51% |
| 2015 Q4 | -204.92 Thousand USD | -33.2% |
| 2015 Q3 | -153.84 Thousand USD | -170.61% |
| 2015 Q1 | -127.65 Thousand USD | 24.29% |
| 2014 Q4 | -168.62 Thousand USD | -201.89% |
| 2014 Q3 | -55.85 Thousand USD | -73.51% |
| 2014 Q2 | -32.19 Thousand USD | -141.3% |
| 2014 Q1 | -13.34 Thousand USD | 58.2% |
| 2014 FY | -270 Thousand USD | -378.72% |
| 2013 Q2 | -4639.00 USD | 69.35% |
| 2013 Q1 | -15.13 Thousand USD | -204.81% |
| 2013 Q3 | -4713.00 USD | -1.6% |
| 2013 FY | -56.4 Thousand USD | -3314.1% |
| 2013 Q4 | -31.91 Thousand USD | -577.13% |
| 2012 Q2 | -1849.00 USD | 81.95% |
| 2012 Q1 | -10.24 Thousand USD | 85.68% |
| 2012 Q3 | -4000.00 USD | -116.33% |
| 2012 Q4 | 14.44 Thousand USD | 461.05% |
| 2012 FY | -1652.00 USD | 98.46% |
| 2011 Q1 | -8808.00 USD | 64.6% |
| 2011 FY | -107.31 Thousand USD | 6.67% |
| 2011 Q4 | -71.55 Thousand USD | -100.08% |
| 2011 Q3 | -35.76 Thousand USD | -1299.2% |
| 2011 Q2 | 2982.00 USD | 133.86% |
| 2010 Q4 | -24.88 Thousand USD | 63.11% |
| 2010 Q3 | -67.44 Thousand USD | -3706.32% |
| 2010 Q2 | -1772.00 USD | 91.51% |
| 2010 Q1 | -20.87 Thousand USD | 80.53% |
| 2010 FY | -114.98 Thousand USD | -0.05% |
| 2009 FY | -114.92 Thousand USD | -318.53% |
| 2009 Q4 | -107.21 Thousand USD | -12195.53% |
| 2009 Q3 | -872.00 USD | 33.99% |
| 2009 Q2 | -1321.00 USD | 76.03% |
| 2009 Q1 | -5510.00 USD | 65.89% |
| 2008 FY | -27.45 Thousand USD | -18.34% |
| 2008 Q2 | -1802.00 USD | 75.17% |
| 2008 Q1 | -7257.00 USD | -98.39% |
| 2008 Q3 | -2245.00 USD | -24.58% |
| 2008 Q4 | -16.15 Thousand USD | -619.6% |
| 2007 Q2 | -9963.00 USD | -35.0% |
| 2007 Q3 | -2129.00 USD | 78.63% |
| 2007 Q4 | -3658.00 USD | -71.82% |
| 2007 FY | -23.2 Thousand USD | -15.89% |
| 2007 Q1 | -7380.00 USD | -20.81% |
| 2006 Q2 | -5514.00 USD | 8.36% |
| 2006 FY | -20.02 Thousand USD | -1012.28% |
| 2006 Q1 | -6017.00 USD | 0.0% |
| 2006 Q3 | -2381.00 USD | 56.82% |
| 2006 Q4 | -6109.00 USD | -156.57% |
| 2005 FY | -1800.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 52.97 Million USD | 107.003% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -486.685% |
| Nascent Biotech, Inc. | -2.08 Million USD | -77.72% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -793.002% |
| Qrons Inc. | -789.34 Thousand USD | -370.038% |
| Rebus Holdings, Inc. | -1.02 Million USD | -263.748% |
| Skye Bioscience, Inc. | -37.64 Million USD | 90.144% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 105.696% |
| Adynxx, Inc. | - USD | Infinity% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -177.83% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 94.073% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 76.623% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 46.866% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 95.051% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 43.58% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1257.062% |
| SQZ Biotechnologies Company | -79.46 Million USD | 95.331% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -28.276% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -103.8% |
| Mesoblast Limited | -87.95 Million USD | 95.782% |
| Marizyme, Inc. | -65.34 Million USD | 94.322% |
| Genus plc | 7.9 Million USD | 146.965% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 65.935% |
| Pharming Group N.V. | -10.54 Million USD | 64.825% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -70.993% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 58.048% |
| ContraFect Corporation | -65.15 Million USD | 94.305% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 24.065% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -114.78% |
| IMV Inc. | -36.48 Million USD | 89.831% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 53.966% |
| MultiCell Technologies, Inc. | -380.07 USD | -976097.543% |
| ONE Bio Corp. | 8.67 Million USD | 142.761% |
| Accustem Sciences Inc. | -3.74 Million USD | 0.966% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 92.822% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -192.805% |
| Q BioMed Inc. | -2.05 Million USD | -80.802% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 0.61% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -55.835% |
| Biomind Labs Inc. | -1.21 Million USD | -205.54% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 93.788% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -19.617% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 53.053% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -90.342% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -24674.533% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 36.22% |
| GB Sciences, Inc. | -1.36 Million USD | -172.475% |
| Alpha Cognition Inc. | -13.77 Million USD | 73.061% |
| HST Global, Inc. | -146.21 Thousand USD | -2437.606% |
| CSL Limited | 2.64 Billion USD | 100.14% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -111.437% |
| Halberd Corporation | -79.67 Thousand USD | -4556.652% |
| Enzolytics Inc. | -2.17 Million USD | -70.442% |
| Agentix Corp. | -1.37 Million USD | -169.99% |
| Resverlogix Corp. | -3.61 Million USD | -2.777% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -16.989% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.743% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 3885.953% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 153.581% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 6.614% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -22.606% |
| AVAX Technologies, Inc. | -6.41 Million USD | 42.151% |
| Zenith Capital Corp. | -10.59 Million USD | 64.985% |
| Genscript Biotech Corporation | -95.47 Million USD | 96.114% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -15863.489% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 10.509% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -6038.644% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -85.038% |
| Kadimastem Ltd | -3.3 Million USD | -12.18% |
| Helix BioMedix, Inc. | -1.05 Million USD | -251.329% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 2.848% |
| BioStem Technologies, Inc. | -8.48 Million USD | 56.263% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -740.62% |
| LadRx Corporation | 400.44 Thousand USD | 1026.532% |
| Cell Source, Inc. | -5.32 Million USD | 30.275% |
| Regen BioPharma, Inc. | 1.02 Million USD | 462.502% |
| Regen BioPharma, Inc. | 1.02 Million USD | 462.502% |
| NovAccess Global Inc. | -4.76 Million USD | 22.204% |
| Affymax, Inc. | -14.42 Million USD | 74.277% |
| Itoco Inc. | -1.86 Million USD | -98.515% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 16.484% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -122.303% |
| Mobile Lads Corp. | -2.26 Million USD | -63.931% |
| CytoDyn Inc. | -49.84 Million USD | 92.556% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -4594.538% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1526.39% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -294.065% |
| SYBLEU INC | -180.3 Thousand USD | -1957.766% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -130.058% |
| International Stem Cell Corporation | -131 Thousand USD | -2732.24% |
| Bioxytran, Inc. | -4.28 Million USD | 13.312% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -6736.369% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -46.635% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 92.282% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -75.508% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -375.131% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -17.116% |
| Neutra Corp. | -233.46 Thousand USD | -1489.204% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 81.715% |
| PureTech Health plc | -65.69 Million USD | 94.353% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 82.554% |
| IXICO plc | -1.17 Million USD | -214.96% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 62.625% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 93.505% |
| CSL Limited | 2.64 Billion USD | 100.14% |
| Cellectis S.A. | -103.17 Million USD | 96.404% |